Liminatus Pharma, Inc. (LIMNW) stock
LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN
$0.04+0.00 (0.00%)
Close on Oct 30, 2026Market cap $189.39MP/E –Yield –
Liminatus Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Liminatus Pharma's operating income for the twelve months ending Jun 30, 2026 was -$4.07M. For fiscal 2025 it was -$2.97M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.97M | – |
| FY2024 | Dec 31, 2024 | -$3.33M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.10M | – |
| Q4 FY2025 | Dec 31, 2025 | -$884.21K | – |
| Q3 FY2025 | Sep 30, 2025 | -$701.17K | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$264.22K | – |
| Q4 FY2024 | Dec 31, 2024 | -$167.08K | – |
| Q3 FY2024 | Sep 30, 2024 | -$543.15K | – |
| Q2 FY2024 | Jun 30, 2024 | -$909.22K | – |
| Q1 FY2024 | Mar 31, 2024 | -$247 | – |